By Morgan Bettex ( December 2, 2008, 12:00 AM EST) -- Novartis Pharmaceutical Corp. has ended its battle with generic-drug maker Mylan Inc. over the patent for the generic version of Novartis' Femara, a drug that treats breast cancer in postmenopausal women, by agreeing to provide Mylan with a license to market the generic before the patent's expiration in 2011....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.